Nectin-4 Targeting ADC Probe for PET Imaging in Solid Tumors

P

Peking University Cancer Hospital & Institute

Status

Not yet enrolling

Conditions

Solid Tumor

Treatments

Drug: 18F-FDG

Study type

Interventional

Funder types

Other

Identifiers

NCT05322512
2022KT25

Details and patient eligibility

About

To study the normal physiological distribution of the probe 124I-EV in human body and its ability to detect overexpression of Nectin-4 in tumor lesions.

Full description

Nectin-4 is highly expressed in different types of cancer and is involved in various aspects of tumor proliferation, angiogenesis, metastasis, tumor recurrence, and DNA repair. Therefore, the development of nuclear medicine molecular probes targeting Nectin-4 is of great significance for improving the specificity and accuracy of Nectin-4 related cancer diagnosis. EV (Enfortumab vedotin) is the first and only drug targeting Nectin-4 so far. By exploring the diagnostic efficacy of 124I-EV in tumors with high nectin-4 expression, it will not only provide evidence for the early diagnosis of tumors. At the same time, the Nectin-4 expression in tumors can be used to develop effective and precise treatment for patients.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. 18-75 years old, male or female;
  2. Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;
  3. The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.
  4. Normal heart function;
  5. Good follow-up compliance;
  6. presence of at least one measurable target lesion according to RECIST1.1 criteria
  7. Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before the start of the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test.

Exclusion criteria

  1. Serious abnormality of liver, kidney and blood;
  2. Pregnant patients;
  3. Pregnant and lactation women;
  1. unable to lie flat for half an hour; 4) Refuse to join the clinical investigator; 5) Suffering from claustrophobia or other mental diseases; 6) Other conditions that researchers deem unsuitable for participating in the experiment.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

124I-EV
Experimental group
Description:
Imaging cohort All enrolled participants will be allocated to undergo three 124I-EV PET/CT scans.
Treatment:
Drug: 18F-FDG

Trial contacts and locations

0

Loading...

Central trial contact

Hua Zhu, Professor; Zhi Yang, Professor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems